Hester Biosciences Posts Strong Q2 FY27 Results; Approves Loan to Africa Arm
Hester Biosciences Ltd 路 Others (Uncategorized) 路 05 Nov 2026, 4:57 pm
Hester Biosciences Posts Strong Q2 FY27 Results; Approves Loan to Africa Arm Hester Biosciences reported a 38% YoY increase in consolidated revenue to INR 979.12m for Q2 FY27 ended 30th Sep'26, with PAT rising 44% YoY to INR 206.31m. Consolidated EBITDA grew 55% YoY to INR 365.16m, delivering a 37% margin. Standalone PAT jumped 131% YoY to INR 166.60m. H1 FY27 consolidated PAT reached INR 1,173.63m, aided by an exceptional gain of INR 857.68m from loan restructuring with the Gates Foundation. The board also approved an unsecured loan of USD 1m at 9% p.a. to wholly-owned subsidiary Hester Africa.
Original exchange filing (PDF)
More announcements from Hester Biosciences Ltd
- 20261105 Transcript of Earnings Conference Call for Q2 & H1 FY27 Financial Results 路 07 Nov 2026
- Audio recording of the Earnings Conference Call for Q2 FY 27 路 05 Nov 2026
- Hester Biosciences Limited has informed the Exchange about Board have approved an Unsecured loan of an aggregate amount of USD 1 million to Hester Biosciences Africa Limited( Hester Africa ), foreign wholly-owned subsidiary in Tanzania, in one or more tranches. 路 05 Nov 2026
- Hester Biosciences Limited has informed the Exchange regarding a press release dated November 05, 2026, titled "20261105 Q2 & H1 FY27 Press Release". 路 05 Nov 2026
- 20261105 Q2 & H1 FY27 Press Release 路 05 Nov 2026
- Hester Biosciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Outcome of Board Meeting held on 5 November 2026 and Financial Results for the Q2 & H1 FY 2026-27 路 05 Nov 2026
- This is to inform you that, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has scheduled investor .... 路 05 Nov 2026
